• "It was incredibly disappointing, " laments retired SmithKline executive Martin Rosenberg, who led the effort.

    FORBES: On The Cover/Top Stories

  • "This vaccine will have a huge impact, " predicts Jean Stephenne, chief of Glaxo- Smithkline's vaccine unit.

    FORBES: Magazine Article

  • SmithKline Beecham's chief scientific officer, George Poste, speaks of pharmacogenomics as the savior of the industry.

    FORBES: Tailor-made drugs

  • Diadexus inherited from SmithKline the new heart risk factor, called Lp-PLA2, or lipoprotein-associated phospholipase A2.

    FORBES: Divining Disease

  • Among the first to recognize this potential was George Poste, former chief scientist for SmithKline Beecham.

    FORBES: Divining Disease

  • The Supreme Court will decide two related, but different questions, in the SmithKline case.

    FORBES: Court Rebuffs Labor Dept. On Sales Rep Overtime

  • In 1996 SmithKline Beecham vowed to discover two new antibiotic classes by 2003.

    FORBES: Germ Warfare

  • The new Glaxo-SmithKline depended for its success on the collaboration of scientists and managers from both companies.

    ECONOMIST: All fall down

  • Intriguingly, even the apparently disastrous collapse of Glaxo-SmithKline hints that managers might be behaving more like shareholders.

    ECONOMIST: All fall down

  • Chief Executive StanleyCrookeStanley Crooke, 60, headed drug development at Smithkline Beckman and anti-cancer research at Bristol-Myers Squibb.

    FORBES

  • Now, it is losing market share rapidly to competitors such as Pfizer's Zoloft and SmithKline Beecham's Paxil.

    ECONOMIST: Too clever by half

  • SmithKline, over whether drug reps should be covered under a specific exemption for salespeople under federal labor laws.

    FORBES: Court Rebuffs Labor Dept. On Sales Rep Overtime

  • WHO, which is starting, in collaboration with Merck and SmithKline Beecham, a massive drug-donation programme for the disease.

    ECONOMIST: A poor diagnosis

  • In 1997 he helped set up Diadexus as a venture between SmithKline and Incyte (each still owns a 20% stake).

    FORBES: Divining Disease

  • Most drugs on the market today target such receptors: SmithKline Beecham's ulcer medicine Tagamet, and American Home Product's hypertension drug Inderal.

    FORBES: Rx: No merger

  • The hastily announced drug merger between Glaxo Wellcome and SmithKline Beecham collapsed when neither boss was prepared to pay second fiddle.

    ECONOMIST: After the deal

  • But when SmithKline researchers screened their compound collection against the novel proteins from staph and strep bacteria, they found few good leads.

    FORBES: On The Cover/Top Stories

  • The Glaxo-SmithKline example may seem extreme, but in many ways was typical.

    ECONOMIST: Sharing the limelight

  • Glaxo and SmithKline may prove to be the exception to this rule.

    ECONOMIST: Pills, potions and promises

  • About the only sympathetic listener he could find was John Horton, a parasitologist at SmithKline and a passionate hunter of affordable cures for tropical parasites.

    FORBES: A cure for neglect

  • Two new giants were created in the drug industry : Glaxo Wellcome announced a union with SmithKline Beecham, and Pfizer completed its acquisition of Warner-Lambert.

    ECONOMIST: A growing world

  • Early experiments suggested that an antisense drug could precisely target cancer cells, but Crooke was unable to reproduce this nascent work in his SmithKline lab.

    FORBES: Antisense and Sensibility

  • That the biggest merger ever was hatched in just ten days should encourage shareholders in Glaxo and SmithKline to look closely at the small print.

    ECONOMIST: Pills, potions and promises

  • In Britain, there is a well-worn path between drug giants such as SmithKline Beecham and Glaxo Wellcome, and executive and non-executive slots on biotech boards.

    ECONOMIST: European biotech: Management shortfall | The

  • SmithKline hopes to test the vaccine at its labs in Belgium.

    FORBES: Castro's props

  • Avandia was invented in the laboratories of Smithkline Beecham, a Glaxo predecessor, two decades ago as one of a class of medicines meant to treat diabetes.

    FORBES: Magazine Article

  • Wyeth-Ayerst, Abbott Laboratories, Merck, SmithKline Beecham and Pfizer have invested heavily in the field, either on their own or by buying or teaming up with smaller, entrepreneurial research outfits.

    FORBES: A hail of silver bullets

  • Colin Witheat, SmithKline's risk manager, says he can halve operating costs by cutting the fees he once paid an insurer to front business around the world.

    ECONOMIST: Lloyd��s of London

  • He instead joined SmithKline Beecham, the predecessor of GSK, in 1996 for the purpose of picking up the management experience he needed to head the next startup.

    FORBES: On The Cover/Top Stories

  • In the fight against prostate cancer, bioinformaticians at SmithKline used their desktop computers to compare genetic data taken from a normal prostate with genetic data taken from a cancerous one.

    FORBES: A hail of silver bullets

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定